Skip to main content
. 2017 Jun 16;8(32):53405–53418. doi: 10.18632/oncotarget.18509

Figure 2. Correlation of mutated-EGFRs with subsequent brain metastases (SBM) in patients without BM at the diagnosis of NSCLC.

Figure 2

(A) The length of overall survival (OS) and the cumulative incidence of SBM. (B) EGFR mutation status and OS. (C) EGFR mutation status and SBM. (D, E) Exon 19 deletion and L858R point mutation, and OS and SBM. Comparisons regarding OS and SBM were done using log-rank test and time-to-event data analysis considering death as a competing risk (†P) (Fine and Gray's sub-distribution hazard model). Note, M = month; Y = year; Mut = mutated; WT = wild-type.